Literature DB >> 1633073

Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.

E Jähnchen1.   

Abstract

1. Plasma concentrations and some haemodynamic parameters known to be affected by nitrates, were monitored in healthy volunteers who received three different dose regimens of isosorbide-5-mononitrate (5-ISMN) over 5 day study periods. 2. No haemodynamic tolerance was found in the 60 mg once-daily dose schedule which produced high plasma concentrations during the daytime but concentrations no greater than 100 ng ml-1 at night. In contrast, a dose regimen of 60 mg followed by 30 mg 12 h later and thereafter every 8 h until the fifth day induced complete haemodynamic tolerance. With this dose regimen the minimum plasma concentrations were never below 300 ng ml-1. A significant attenuation of haemodynamic effects was also found with the third dose regimen, 60 mg followed by 30 mg 6 h later for 5 days, which produced minimum plasma concentrations of between 100 ng ml-1 to 300 ng ml-1; the degree of attenuation rose as trough plasma concentrations increased. 3. In conclusion, 60 mg 5-ISMN in a controlled-release (Durules) preparation given once daily was the only dose regimen not inducing nitrate tolerance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633073      PMCID: PMC1381217          DOI: 10.1111/j.1365-2125.1992.tb04143.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

Review 1.  Long-term therapeutic efficacy with once-daily isosorbide-5-mononitrate (Imdur).

Authors:  M J Kendall
Journal:  J Clin Pharm Ther       Date:  1990-06       Impact factor: 2.512

2.  Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.

Authors:  F Wagner; F Siefert; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nitrate therapy in stable angina pectoris.

Authors:  J O Parker
Journal:  N Engl J Med       Date:  1987-06-25       Impact factor: 91.245

4.  Tolerance to organic nitrates.

Authors:  J Abrams
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

5.  Tolerance development during isosorbide dinitrate treatment: can it be circumvented?

Authors:  W Rudolph; R Blasini; G Reiniger; U Brügmann
Journal:  Z Kardiol       Date:  1983
  5 in total
  2 in total

1.  Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration.

Authors:  G Lehmann; G Reiniger; H Wolf; A Beyerle; W Rudolph
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

2.  The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.

Authors:  W McClennen; B Hornestam; U E Jonsson; P Held
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.